PHAGO - a new approach to help patients with Alzheimer's disease

It was only recently discovered that the innate immunoreceptor genes TREM2 and CD33/SGLEC3 play a role in Alzheimer's disease. However, the significance of the identified genes and of the cellular mechanism has not been sufficiently investigated. The PHAGO project is designed to close these knowledge gaps and develop new tools and test methods that work on these immune receptors and open the way to the development of drugs that inhibit the course of the disease. This will allow new therapies for Alzheimer's patients. The project is funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Union and the Federation of Pharmaceutical Industries in Europe (EFPIA).

Project duration

November 2016 to October 2021